Cargando…

A Phase II study of Viagenpumatucel-l (HS-110) in combination with low-dose Cyclophosphamide versus physician's choice in patients with advanced non-small cell lung cancer

Detalles Bibliográficos
Autores principales:	Cohen, Roger B, Nemunaitis, John, Gabrail, Nashat, Bazhenova, Lyudmila, Schreiber, Taylor H, Price, Melissa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288753/ http://dx.doi.org/10.1186/2051-1426-2-S3-P82

Ejemplares similares

APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide–based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial
por: Schnadig, Ian D, et al.
Publicado: (2017)

Phase I study of patients with non-muscle invasive bladder cancer (NMIBC) treated with vesigenurtacel-L (HS-410) after Bacillus Calmette-Guérin (BCG)
por: Steinberg, Gary, et al.
Publicado: (2015)

Durable Response to Maintenance Treatment Comprised of Viagenpumatucel-L, Nivolumab, Ramucirumab, and Docetaxel in a PD-L1-Low Advanced-Stage Non-Small-Cell Lung Cancer: A Case Report
por: Gollard, Russell, et al.
Publicado: (2023)

New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
por: Villanueva, Nicolas, et al.
Publicado: (2018)

Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
por: Giustini, Nicholas, et al.
Publicado: (2021)

Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial
por: Raftopoulos, Harry, et al.
Publicado: (2014)

PB2224: ABBV-744 ALONE OR IN COMBINATION WITH RUXOLITINIB OR NAVITOCLAX IN PATIENTS WITH MYELOFIBROSIS: A PHASE 1B STUDY
por: Mascarenhas, John, et al.
Publicado: (2023)

A Phase I/II study of vesigenurtacel-l (hs-410) or placebo in combination with Bacillus Calmette-Guérin (BCG) in patients with non-muscle invasive bladder cancer (NMIBC)
por: Steinberg, Gary D, et al.
Publicado: (2014)

Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials
por: Gabrail, Nashat, et al.
Publicado: (2015)

Physician-controlled costs: the choice of equipment used for atrial fibrillation ablation
por: Winkle, Roger A., et al.
Publicado: (2013)

Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC
por: Yun, Karen M, et al.
Publicado: (2022)

Low-dose cyclophosphamide-induced acute hepatotoxicity
por: Subramaniam, S. Ravih, et al.
Publicado: (2013)

High Dose Cyclophosphamide Treatment for Autoimmune Disorders
por: Brodsky, Robert A.
Publicado: (2002)

Low-Dose Cyclophosphamide Associated With Hyponatremia and Hepatotoxicity
por: DeChiara, James R, et al.
Publicado: (2023)

A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer
por: Garon, Edward B, et al.
Publicado: (2016)

FGF8 morphogen gradients are differentially regulated by heparan sulphotransferases Hs2st and Hs6st1 in the developing brain
por: Chan, Wai-Kit, et al.
Publicado: (2017)

Water Intoxication Following Low-Dose Intravenous Cyclophosphamide
por: Koo, Tai Yeon, et al.
Publicado: (2007)

Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer
por: Khan, O A, et al.
Publicado: (2011)

The effect of APN, hs-CRP and APN/hs-CRP in periodontitis with DAA
por: Cheng, Rui, et al.
Publicado: (2023)

Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer
por: Khan, O A, et al.
Publicado: (2011)

Infrastructuremetallic-structures: HS
Publicado: (2003)

Infrastructuremetallic-structures: HS
Publicado: (2003)

Infrastructuremetallic-structures: HS
Publicado: (2003)

Infrastructuremetallic-structures: HS
Publicado: (2003)

Infrastructuremetallic-structures: HS
Publicado: (2003)

Infrastructuremetallic-structures: HS
Publicado: (2003)

Infrastructuremetallic-structures: HS
Publicado: (2003)

Infrastructuremetallic-structures: HS
Publicado: (2003)

Infrastructuremetallic-structures: HS
Publicado: (2003)

Infrastructuremetallic-structures: HS
Publicado: (2003)

Infrastructuremetallic-structures: HS
Publicado: (2004)

Infrastructuremetallic-structures: HS
Publicado: (2004)

Infrastructuremetallic-structures: HS
Publicado: (2004)

O & H’s Teeth
Publicado: (1858)

Physician Career Choice and Satisfaction: Empirical Studies of Practicing Physicians
por: Pope, Barbara M.
Publicado: (2020)

Tiered Physician Network Plans and Patient Choices of Specialist Physicians
por: Prager, Elena, et al.
Publicado: (2023)

The dose of cyclophosphamide for treating paraquat-induced rat lung injury
por: Choi, Jae-Sung, et al.
Publicado: (2013)

Young Doctor Movements: motives for membership among aspiring and young family physicians
por: Yakubu, Kenneth, et al.
Publicado: (2015)

Choice is simply yours—Physician's perception
por: Dwivedi, Shridhar
Publicado: (2011)

Physician choices in pulmonary embolism testing
por: Zarabi, Sahar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2p4cc61jp6h22on8m8mlbjftj1